Compare Cassava Sciences Inc (FLNA) vs Live Nation Entertainment, Inc. (LYV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Live Nation Entertainment, Inc. — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Live Nation Entertainment, Inc. trades at $178.7 (market cap $41.53B). The key difference: Live Nation Entertainment, Inc. is far larger — about 781.5× Cassava Sciences Inc's market cap, and Live Nation Entertainment, Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | LYV | |
|---|---|---|
Market Cap | $53.14M | $41.53B |
Sector | Health | Industrials |
52-Week High | $4.64 | $186.59 |
52-Week Low | $1.09 | $125.61 |
Enterprise Value | -$33.43M | $43.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Live Nation Entertainment (LYV) trades at $178.62, down 1.62% on the day, with a bullish technical signal supported by moving averages. The company reported $25.2B in 2025 revenue but faces profitability challenges with a net margin of just 0.33% and negative ROE of -24.68%. Recent earnings misses and a $450M legal charge have pressured results, though strong concert demand and ticket sales growth provide optimism.
Analyst consensus remains strongly bullish with 88.6% buy ratings and a $200.20 price target, representing 12% upside. Key risks include execution on profitability, competitive pressures, and discretionary spending sensitivity. The stock's high P/E of 117.5 reflects growth expectations but demands careful monitoring of margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →
